Alzheimer's disease cooperative study

  • Description
  • Details
  • Subprojects
  • History
  • Publications
  • Patents
  • Trials
Project Title: Alzheimer's disease cooperative study
Project Number: 4U19AG010483-25
Project web address: Follow on NIH
Project Description:
The overall aim of the ADCS is to advance research in the development of interventions that might be useful for treating, delaying, or preventing AD, particularly interventions that might not be developed by industry. In particular, the ADCS has focused on instrument and trial methodology, and the testing of potential therapeutics that might not otherwise be studied by the pharmaceutical industry. For the coming grant cycle, the ADCS will continue its efforts to advance therapeutics through controlled clinical trials, development o novel instruments and trial designs, recruitment efforts (with particular attention to recruitment f minority subjects). The organization will continue its recent emphasis on collaboration and data sharing. Specific Aims: Aim 1: Test interventions to Improve cognition, slow the rate of decline, or delay/prevent the onset of AD. Three of the four projects in this application aim to slow disease progression. Aim 2: Test an intervention to ameliorate behavioral symptoms. We will extend promising early results supporting an adrenergic approach amelioration of behavioral symptoms with a multicenter trial of prazosin. Aim 3: Design new instruments for use in clinical trials. For the present cycle, we have incorporated instrument development into our largest project, the A4 trial. Aim 4: Develop novel and innovative approaches to AD clinical trial design. The A4 trial utilizes a new trial design to test a leading intervention at the earliest feasible stge of disease, preclinical AD. Aim 5: Develop novel and innovative approaches to AD clinical trial analysis. The Biostatistics Core will continue efforts to advance analytical approaches to AD trial design. Work will continue on optimal modeling of longitudinal data, including novel methods to link diverse datasets. Aim 6:.Expand the range of individuals studied in AD studies to include at-risk individuals and those with MCI. The ADCS has focused its methodological research on early-stage trials, and for this cycle, the two largest projects target preclinical AD and mild cognitive impairment. Aim 7: Enhance the recruitment of minority groups into AD studies. For the coming cycle, the ADCS Minority Recruitment Core will expand outreach efforts, and we will require sites to meet minority enrollment targets in our two largest trials.
Project Terms:
actigraphy adrenergic agents affect age aging alzheimer's disease alzheimer's disease risk amyloid attention base behavior assessment behavioral symptoms biostatistics core biotechnology clinical course of disease clinical trials clinical trials design cognition cognitive change collaborations computerized controlled clinical trials cooperative study data data analyses data set dementia design development device or instrument development disease disease progression drug industry drug kinetics effective therapy enrollment epidemic epidemiology europe exercise experience family funding goals grant healthcare home environment improved individual industry innovation instrument intervention laboratory study link meetings methodology methods mild cognitive impairment minority enrollment minority groups minority recruitment minority subjects modeling multicenter trials neuroimaging non-demented novel outreach patient outcomes assessments pharmacodynamics pharmacologic substance pharmacological treatment phase phase 2 study placebos population prazosin pre-clinical prevent prevention process programs publications research research design research personnel resources risk safety sampling studies sharing data site staging testing therapeutic therapeutic trials therapy development trial design underrepresented minority work
Project Title: Alzheimer's disease cooperative study
Project Number: 4U19AG010483-25
Project web address: Follow on NIH
Organization: University Of California San Diego, United States, California, LA JOLLA
Principal Investigators (PI): Feldman Howard, US
Project Categories:
Natural Sciences > Aging Diseases and Pathology > Neurodegenerative diseases > Alzheimer's disease
Other Information:
Fiscal Year: 1997
Project Start Date: 1 July 1997
Project End Date: 28 February 2018
Project program: Research Program--Cooperative Agreements
Project Funding Information:
Funding Mechanism: Non-SBIR/STTR RPGs
Year Funding Organization Total Funding, $
2016 NIH - National Institute On Aging $10,006,406
Project Title: Alzheimer's disease cooperative study
Project Number: 4U19AG010483-25
Project web address: Follow on NIH
Title FY Funding
Med & safety core 2016 $1029425
Recruitment core 2016 $251698
Biostat core 2016 $207468
Clinical operations core 2016 $501124
Biomarker core 2016 $220796
Exercise trail 2016 $697720
Imaging core 2016 $361001
Prazosin for agitation in alzheimer's disease 2016 $1376601
Administrative core 2016 $1812321
Anti-amyloid treatment in asymptomatic alzheimers disease 2016 $3286257
Informatics core 2016 $261995
Project Title: Alzheimer's disease cooperative study
Project Number: 4U19AG010483-25
Project web address: Follow on NIH
Title Journal Year Country Rel
Resveratrol for Alzheimer's disease. Ann N Y Acad Sci 2017 united states
A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012. JAMA Intern Med 2017 united states
Computerized Cognitive Testing for Use in Clinical Trials: A Comparison of the NIH Toolbox and Cogstate C3 Batteries. J Prev Alzheimers Dis 2017 france
Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals. J Neurosci 2017 united states
Neuroimaging markers associated with maintenance of optimal memory performance in late-life. Neuropsychologia 2017 england
The association between tau PET and retrospective cortical thinning in clinically normal elderly. Neuroimage 2017 united states
Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA 2017 united states
Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case. Acta Neuropathol Commun 2017 england
Potential implications of practice effects in Alzheimer's disease prevention trials. Alzheimers Dement (N Y) 2017 united states
Influence of preeclampsia and late-life hypertension on MRI measures of cortical atrophy. J Hypertens 2017 england
Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease. Alzheimers Dement 2016 united states
The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease. Alzheimer Dis Assoc Disord 2016 united states
Functional Impact of Corticotropin-Releasing Factor Exposure on Tau Phosphorylation and Axon Transport. PLoS One 2016 united states
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 2016 england
An MRI-Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. J Neuroimaging 2016 united states
CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol 2016 england
Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials. J Alzheimers Dis 2016 netherlands
Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016 united states
Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimers Dement 2016 united states
The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials. J Prev Alzheimers Dis 2016 france
"New Old Pathologies": AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS). J Neuropathol Exp Neurol 2016 england
Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol 2015 united states
Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. Alzheimers Res Ther 2015 england
Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. Neuropsychologia 2015 england
HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study. Mol Psychiatry 2015 england
Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis 2015
Establishing Clinical Relevance in Preclinical Alzheimer's Disease. J Prev Alzheimers Dis 2015
Reproductive Stage and Modulation of Stress-Induced Tau Phosphorylation in Female Rats. J Neuroendocrinol 2015 united states
Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor. J Alzheimers Dis 2015 netherlands
Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimers Dement 2015 united states
Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimers Dement 2015 united states
Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther 2015 england
Impact of CRFR1 Ablation on Amyloid-? Production and Accumulation in a Mouse Model of Alzheimer's Disease. J Alzheimers Dis 2015 netherlands
White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiol Aging 2015 united states
Corticotropin-Releasing Factor Receptor-1 Antagonism Reduces Oxidative Damage in an Alzheimer???s Disease Transgenic Mouse Model. J Alzheimers Dis 2015 netherlands
Alzheimer's disease progression by geographical region in a clinical trial setting. Alzheimers Res Ther 2015 england
Peripheral and central effects of ?-secretase inhibition by semagacestat in Alzheimer's disease. Alzheimers Res Ther 2015 england
Advances in Alzheimer's disease drug development. BMC Med 2015 england
Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Ann Clin Transl Neurol 2015 united states
Amyloid and APOE ?4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 2014 united states
Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. J Int Neuropsychol Soc 2014 england
Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease. Am J Alzheimers Dis Other Demen 2014 united states
The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline. Dement Geriatr Cogn Dis Extra 2014 switzerland
Estimating long-term multivariate progression from short-term data. Alzheimers Dement 2014 united states
Association of plasma and cortical amyloid beta is modulated by APOE ?4 status. Alzheimers Dement 2014 united states
The end of Alzheimer's disease--from biochemical pharmacology to ecopsychosociology: a personal perspective. Biochem Pharmacol 2014 england
Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 2014 united states
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 2014 united states
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med 2014 united states
Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. J Am Geriatr Soc 2014 united states
Subjective cognitive concerns, episodic memory, and the APOE ?4 allele. Alzheimers Dement 2014 united states
Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease. Alzheimers Dement 2014 united states
Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement 2014 united states
Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 2014 united states
The A4 study: stopping AD before symptoms begin? Sci Transl Med 2014 united states
Clinical trial of an inhibitor of RAGE-A? interactions in Alzheimer disease. Neurology 2014 united states
Synergistic effect of ?-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 2014 united states
Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol 2014 england
Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. PLoS One 2013 united states
Developing dementia prevention trials: baseline report of the Home-Based Assessment study. Alzheimer Dis Assoc Disord 2013 united states
Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology 2013 united states
Improved statistical power of Alzheimer clinical trials by item-response theory: proof of concept by application to the activities of daily living scale. Alzheimer Dis Assoc Disord 2013 united states
Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology 2013 united states
A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013 united states
Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study. Int J Clin Pract 2013 england
Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J Neural Transm (Vienna) 2012 austria
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 2011 united states
Sample size requirements for training to a kappa agreement criterion on clinical dementia ratings. Alzheimer Dis Assoc Disord 2010 united states
A study of medication-taking and unobtrusive, intelligent reminding. Telemed J E Health 2009 united states
Declining financial capacity in mild cognitive impairment: A 1-year longitudinal study. Neurology 2009 united states
Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer's disease. J Geriatr Psychiatry Neurol 2003 canada
A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003 united states
The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease. J Sleep Res 2003 england
Project Title: Alzheimer's disease cooperative study
Project Number: 4U19AG010483-25
Project web address: Follow on NIH
Title Year
Project Title: Alzheimer's disease cooperative study
Project Number: 4U19AG010483-25
Project web address: Follow on NIH
Title Phase Year
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study N/A 2013
Exercise in Adults With Mild Memory Problems N/A 2013